A Prospective, Multi-Center, Open-Label, Randomized, Controlled Clinical Trial Comparing the Efficacy and Safety in Subjects With Type 1 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Basal and Prandial Insulin Over a 52-Week Treatment Period and a 4-Week Follow Up.

Trial Profile

A Prospective, Multi-Center, Open-Label, Randomized, Controlled Clinical Trial Comparing the Efficacy and Safety in Subjects With Type 1 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Basal and Prandial Insulin Over a 52-Week Treatment Period and a 4-Week Follow Up.

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Nov 2014

At a glance

  • Drugs Insulin (Primary) ; Insulin aspart
  • Indications Type 1 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Sponsors MannKind Corporation
  • Most Recent Events

    • 30 Sep 2009 Results presented at the 45th Annual Meeting of the European Association for the Study of Diabetes (EASD).
    • 06 Jun 2009 Results were presented at the American Diabetes Association's 69th Scientific Sessions, according to a MannKind media release.
    • 05 Jun 2009 Results presented at the 69th Annual Scientific Sessions of the American Diabetes Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top